中达安 reported revenue of ¥0.26B for the period ended 2026-06-30, -15.5% year on year. Net income was ¥0.02B, a 6.6% net margin on a 28.6% gross margin. The largest revenue line is 电力监理 at 25% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.26B | -15.5% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | +439.8% |
| Gross margin | 28.6% | Net margin 6.6% |
| Revenue Q/Q | +18.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 电力监理 | ¥0.06B | 24.7% |
| 土建监理 | ¥0.06B | 22.6% |
| 水利监理 | ¥0.04B | 15.9% |
| 咨询与代建 | ¥0.04B | 15.2% |
| 通信监理 | ¥0.04B | 14.2% |
| 招标代理 | ¥0.01B | 4.1% |
| 电力勘察 | ¥0.01B | 2.9% |
| 光伏发电 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.18B | 71.4% |
| R&D | ¥0.02B | 9.0% |
| SG&A | ¥0.04B | 15.2% |
| Tax & other | ¥0.00B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.16B |
| Total liabilities | ¥0.80B |
| Shareholders' equity | ¥0.36B |
| Equity / assets | 30.9% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | 36% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies